Please assess the completion status of the following clinical trial:

Trial Title: The Application of Zishen Yutai Pill in Aged Women Undergoing IVF-ET

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* infertile women aged ≥35 and ≤42 years;~* intend to undergo IVF/ICSI-ET (GnRH-a long protocol or GnRH-ant protocol);~* BMI\<28kg/m2;~* bilateral ovaries exist;~* patients who voluntarily signed the informed consent and agreed to be followed up as required by the study protocol.~Exclusion Criteria:~* repeated implantation failure (previous three times or more IVF/ICSI-ET failure);~* adenomyosis, uterine line constricted by uterine fibroid;~* untreated bilateral hydrosalpinx;~* endometrial diseases that have not been cured ;~* known diseases that are not suitable for undergoing assisted reproductive technology or at the present not suitable for pregnancy;~* patients who have taken traditional Chinese medicine or Chinese patent medicine for infertility treatment in the last month(30 days).~Exit Criteria:~* subjects who have adverse events cannot be tolerated;~* severe breach of the protocol;~* for subjects who exit due to personal or unpredictable reasons, please describe specific details;~* subjects considered inappropriate to continue to participate in the study for other medical reasons.

- Gender: FEMALE
- Minimum Age: 35 Years
- Maximum Age: 42 Years
- Healthy Volunteers: f

Study Arms:
- Zishen Yutai pill group (Type: EXPERIMENTAL): Patients who undergo the long-term protocol will start taking Zishen Yutai Pill on the day of pituitary suppression, 5g three times a day (Stopping on the first 1-4 days of menstruation), and patients who undergo the antagonist protocol will start taking Zishen Yutai Pill on the 19th to 23rd day of the previous menstruation cycle, 5g three times a day (Stopping on the first 1-4 days of menstruation). The drug will be taken till 2 weeks after transplantation. If the test result is confirmed as biochemical pregnancy (HCG\>50 IU/L), patients continue to take pills till 3 weeks after the clinical pregnancy determined by the ultrasound. If it is determined that the pregnancy test is negative, stop the drug.
- Placebo group (Type: PLACEBO_COMPARATOR): Patients who undergo the long-term protocol will start taking Placebo on the day of pituitary suppression, 5g three times a day (Stopping on the first 1-4 days of menstruation), and patients who undergo the antagonist protocol will start taking Placebo on the 19th to 23rd day of the previous menstruation cycle, 5g three times a day (Stopping on the first 1-4 days of menstruation). The drug will be taken till 2 weeks after transplantation. If the test result is confirmed as biochemical pregnancy (HCG\>50 IU/L), patients continue to take pills till 3 weeks after the clinical pregnancy determined by the ultrasound. If it is determined that the pregnancy test is negative, stop the drug.

Based on this trial design, predict the completion outcome and termination type (if applicable).